Clinical and pharmacological group: & nbsp

Stimulators of hematopoiesis

Included in the formulation
  • Neostim®
    lyophilizate in / in PC 
    FDS Pharma     United Kingdom
  • АТХ:

    L.03.A.A.03   Molgrastim

    Pharmacodynamics:

    Promotes the proliferation and differentiation of granulocyte precursors, macrophages and monocytes. Strengthens the phagocytosis of mature neutrophils, increasing the severity of the "respiratory explosion", due to which up to 90% of the active forms of oxygen that activates the phagocytosis process are formed.

    It has an immunotropic effect, accelerating the maturation of T-lymphocytes. Increases cytotoxicity with respect to malignant cells. Enhances the expression of antigens II class HLA on the surface of monocytes, increases the production of antibodies.

    Normalizes the process of myelopoiesis in myelodysplasia. Reduces the risk of developing deep neutropenia. Reduces the recovery period after bone marrow transplantation in connection with acute leukopenia.

    Reduces the level of albumins.

    Pharmacokinetics:

    After subcutaneous or intravenous administration, the maximum concentration in the blood plasma is reached after 3 hours.

    Therapeutic effect develops in 2-4 days after administration.

    The half-life is 3 hours with subcutaneous injection, with intravenous - 1 hour. Elimination by the kidneys.

    Indications:

    It is used for the treatment and prevention of neutropenia in aplastic anemia, after bone marrow transplantation,with infections, including HIV.

    II.C81-C96.C90   Multiple myeloma and malignant plasma cell neoplasms

    II.C81-C96.C91   Lymphoid leukemia [lymphocytic leukemia]

    III.D70-D77.D72   Other disorders of white blood cells

    Contraindications:

    Age to 18 years, myeloid leukemia, autoimmune diseases, lung diseases, pregnancy and lactation, individual intolerance.

    Carefully:

    Hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Subcutaneously and intravenously, at 5-10 mcg / kg per day.

    The highest daily dose: 10 mcg / kg per day.

    The highest single dose: 10 mcg / kg per day.

    Side effects:

    Central and peripheral nervous system: asthenia, weakness, rarely - headache, dizziness, convulsions.

    Hemopoietic system: thrombocytopenia, eosinophilia.

    Respiratory system: dyspnoea.

    The cardiovascular system: arterial hypotension, pericarditis, rarely - cerebrovascular disorders, heart failure, peripheral edema.

    Digestive system: nausea, anorexia, diarrhea.

    Musculoskeletal system: myalgia, arthralgia.

    Dermatological reactions: a rash.

    Allergic reactions.

    Overdose:

    Increased side effects.

    Treatment is symptomatic.

    Interaction:

    When used simultaneously with drugs that have a high degree of binding to albumin, increases the risk of proteinemia.

    Special instructions:

    The drug is used only in the conditions of a specialized hospital.

    Instructions
    Up